INC Research Holdings (Nasdaq:INCR), the Raleigh-based contract research organization reported revenue of $234.5 million and earnings of 58 cents a share, beating analyst consensus estimates aby 14 cents.

The company’s revenue rose 12.8 percent compared to the same period last year.

The company does strategic clinical development, providing a range of Phase I through Phase IV clinical development services for the biopharmaceutical and medical device industry.

“INC Research delivered another consecutive quarter of record strong results,” stated CEO Jamie Macdonald in a statement.

“These results further underscore the success of our approach in leveraging therapeutically-aligned teams, our proven Trusted Process clinical trial methodology and best-in-class site relationships to deliver unmatched Phase I-IV global clinical development programs for our customers.

“In a robust market and with strong growth prospects, we are confident in the future outlook for the Company and as a result are increasing our earnings expectations for full-year 2015.”

It forecast full year net service revenue guidance to from $910 million to $914 million and adjusted diluted EPS guidance to $191 to $1.97.